InflaRx
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell InflaRx and other ETFs, options, and stocks.About IFRX
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab.
CEONiels Christoph Riedemann
CEONiels Christoph Riedemann
Employees74
Employees74
HeadquartersJena, Thueringen
HeadquartersJena, Thueringen
Founded2007
Founded2007
Employees74
Employees74
IFRX Key Statistics
Market cap78.55M
Market cap78.55M
Price-Earnings ratio-1.11
Price-Earnings ratio-1.11
Dividend yield—
Dividend yield—
Average volume895.43K
Average volume895.43K
High today$1.24
High today$1.24
Low today$1.13
Low today$1.13
Open price$1.24
Open price$1.24
Volume867.75K
Volume867.75K
52 Week high$2.82
52 Week high$2.82
52 Week low$0.7113
52 Week low$0.7113
Stock Snapshot
InflaRx(IFRX) stock is priced at $1.17, giving the company a market capitalization of 78.55M. It carries a P/E multiple of -1.11.
As of 2025-12-02, InflaRx(IFRX) stock has fluctuated between $1.13 and $1.24. The current price stands at $1.17, placing the stock +3.5% above today's low and -5.7% off the high.
InflaRx(IFRX) shares are trading with a volume of 867.75K, against a daily average of 895.43K.
In the last year, InflaRx(IFRX) shares hit a 52-week high of $2.82 and a 52-week low of $0.71.
In the last year, InflaRx(IFRX) shares hit a 52-week high of $2.82 and a 52-week low of $0.71.
Analyst ratings
88%
of 8 ratingsBuy
87.5%
Hold
12.5%
Sell
0%
People also own
Based on the portfolios of people who own IFRX. This list is generated using Robinhood data, and it’s not a recommendation.